1-9 of 9
Luis Fayad, M.D.
Close
Sort by
Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.
Journal: Blood
Blood (2009) 114 (22): 1714.
https://doi.org/10.1182/blood.V114.22.1714.1714
Published: 2009
Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD
Journal: Blood
Blood (2009) 114 (22): 3922.
https://doi.org/10.1182/blood.V114.22.3922.3922
Published: 2009
Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 835.
https://doi.org/10.1182/blood.V112.11.835.835
Published: 2008
Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2006) 108 (11): 2749.
https://doi.org/10.1182/blood.V108.11.2749.2749
Published: 2006
Journal Articles

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Shyam Teegala, MD, Xiao Zhou, MD, PhD, Auris Huen, PHARMD, Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.
Journal: Blood
Blood (2006) 108 (11): 4103.
https://doi.org/10.1182/blood.V108.11.4103.4103
Published: 2006
Journal Articles

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Auris Huen, PharmD, Xiao Zhou, MD, PhD, Shyam Teegala, M.D., Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.
Journal: Blood
Blood (2006) 108 (11): 3994.
https://doi.org/10.1182/blood.V108.11.3994.3994
Published: 2006
Journal Articles

Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study Sphingosomal Vincristine in CHOP +/− Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study.

Maria Alma Rodriguez, M.D., Andreas Sarris, M.D., Nam H. Dang, M.D., Luis Fayad, M.D., Andre Goy, M.D., Fredrick Hagemeister, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Felipe Samaniego, M.D., Anas Younes, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2004) 104 (11): 4602.
https://doi.org/10.1182/blood.V104.11.4602.4602
Published: 2004
Journal Articles

Long-Term Safety and Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after ABVD Chemotherapy in Patients with Hodgkin Lymphoma.

Anas Younes, M.D., Luis Fayad, M.D., Jorge Romaguera, M.D., Barbara Pro, M.D., Andre Goy, M.D., Nam Dang, M.D., Michael Wang, M.D.
Journal: Blood
Blood (2004) 104 (11): 4646.
https://doi.org/10.1182/blood.V104.11.4646.4646
Published: 2004
Journal Articles

Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Luis Fayad, M.D, James Liebmann, M.D, Manuel Modiano, M.D, Gary I. Cohen, M.D, Barbara Pro, M.D, Jorge Romaguera, M.D, Cristina Davite, BSc, Margarita Lymboura, BSc, Silvia Comis, M.D, Bernard L. Laffranchi, M.D
Journal: Blood
Blood (2004) 104 (11): 1324.
https://doi.org/10.1182/blood.V104.11.1324.1324
Published: 2004